TABLE OF CONTENTS
CHAPTER 1 EXECUTIVE SUMMARY 3
- 1.1 Scope 3
- 1.2 Datamonitor insight into the strategic opportunities available in the sleep disorders market 3
- Conclusion 8
CHAPTER 2 INSOMNIA 15
- 2.1 Introduction 15
- 2.2 Disease Overview 15
- 2.3 Epidemiology 17
- Prevalence of insomnia 17
- Insomnia in the general population 17
- Insomnia in the elderly 18
- Insomnia in primary care 19
- Insomnia in other conditions 19
- Diagnosis rate 20
- Treatment rate 21
- Conclusion 22
- 2.4 Current Therapies 23
- Ambien/Stilnox (zolpidem) 23
- The future: a number of strategic issues will impact Ambien revenues 23
- Sonata (zaleplon) 25
- Benzodiazepines 27
- Drugs used off-label 28
- Case study: Remeron (mirtazapine) 28
- 2.5 Pipeline Compounds 29
- Indiplon 30
- APSS 2003: the first look at fullscale indiplon data 31
- Strategic analysis 31
- Conclusion 35
- Estorra 35
- APSS 2003: outlining the unique data for Estorra 35
- Recommended co-marketing partners 37
- Conclusion 38
- Indiplon vs. Estorra: a strategic conclusion 38
- TAK-375 39
CHAPTER 3 NARCOLEPSY 41
- 3.1 Disease Overview 41
- 3.2 Epidemiology 42
- Prevalence of narcolepsy 42
- Diagnosis rate 43
- Conclusion 44
- 3.3 Current Therapies 45
- Provigil (modafinil) 45
- An expanded label: key to the revenue prospects for Provigil 46
- APA 2003: establishing future growth strategies for Provigil 46
- Single isomer Provigil: the best method to stop generic substitution? 49
- Conclusion 50
- Xyrem (sodium oxybate) 51
- CNS stimulants 52
- Methylphenidate 52
- Adderall 53
- Others 53
- Agents used off-label 53
- Cylert (pemoline) 53
- Eldepryl (selegiline) 53
- Antidepressants 54
- 3.4 Pipeline Compounds 54
CHAPTER 4 RESTLESS LEG SYNDROME 56
- 4.1 Disease Overview 56
- Primary features 56
- Associated features 56
- 4.2 Epidemiology 57
- Prevalence of restless leg syndrome 57
- RLS in the US 57
- RLS in the EU 58
- RLS in Japan 58
- Diagnosis rate 59
- Treatment rate 59
- Conclusion 60
- 4.3 Current Therapies 62
- Requip (ropinirole) 62
- AAM 2003: targeting the key Requip prescribers 62
- Differentiation is the key for long-term growth 63
- Mirapex (pramipexole) 63
- Building the data in RLS 64
- L-dopa 65
- An opportunity for Novartis? 65
- Neurontin (gabapentin) 66
- Encouraging off-label use in RLS: the need for strong data 66
- Why did Pfizer target Neurontin at RLS? 67
- Other compounds 68
- Opioids 68
- 4.4 Pipeline Compounds 68
- Rotigotine CDS 68
- 4.5 Strategic Issues 69
- Comparative data will change the current fragmented market dynamics 70
- Educating physicians is key to generating market expanse 70
- Future research opportunities 71
CHAPTER 5 APPENDIX A: ABOUT THE REPORT 72
- 5.1 Contributing Experts 72
- 5.2 Bibliography 72
- Insomnia 72
- Narcolepsy 74
- Restless Leg Syndrome 76
- 5.3 Websites 78
- 5.4 Table of tables 78
- 5.5 Table of figures 79
CHAPTER 6 APPENDIX B: ABOUT DATAMONITOR 80
- 6.1 About Datamonitor 80
- About Datamonitor Healthcare 80
- Datamonitor Healthcare' s research and analysis methodologies 81
- 6.2 Datamonitor Healthcare' s therapy area capabilities 81
- About the CNS analysis team 82
- Datamonitor Healthcare' s Consulting expertise 84
- Datamonitor' s Therapeutic Consulting expertise 85
- Key therapy team members 85
- Nick Alcock, Managing Analyst, Central Nervous System 85
- David Abramson, Therapeutic Lead Consultant 86
- Disclaimer 88
|
Related Report
|
View Cart
